Morgan Stanley’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-319,579
| Closed | -$15.3M | – | 6905 |
|
|
2020
Q1 | $15.3M | Sell |
319,579
-4,850
| -1% | -$226K | ﹤0.01% | 1472 |
|
|
2019
Q4 | $15.2M | Buy |
324,429
+307,808
| +1,852% | +$13.6M | ﹤0.01% | 1925 |
|
|
2019
Q3 | $393K | Buy |
16,621
+9,748
| +142% | +$289K | ﹤0.01% | 4804 |
|
|
2019
Q2 | $206K | Sell |
6,873
-96,985
| -93% | -$2.22M | ﹤0.01% | 5013 |
|
|
2019
Q1 | $2.33M | Buy |
103,858
+81,546
| +365% | +$1.75M | ﹤0.01% | 3464 |
|
|
2018
Q4 | $406K | Sell |
22,312
-3,700
| -14% | -$58.1K | ﹤0.01% | 4920 |
|
|
2018
Q3 | $470K | Sell |
26,012
-5,741
| -18% | -$68K | ﹤0.01% | 5039 |
|
|
2018
Q2 | $316K | Sell |
31,753
-4,249
| -12% | -$29.3K | ﹤0.01% | 5352 |
|
|
2018
Q1 | $191K | Buy |
36,002
+11,702
| +48% | +$83.6K | ﹤0.01% | 5488 |
|
|
2017
Q4 | $207K | Buy |
24,300
+9,259
| +62% | +$114K | ﹤0.01% | 5394 |
|
|
2017
Q3 | $220K | Buy |
15,041
+4,109
| +38% | +$62.1K | ﹤0.01% | 5315 |
|
|
2017
Q2 | $205K | Buy |
10,932
+96
| +0.9% | +$2.17K | ﹤0.01% | 5316 |
|
|
2017
Q1 | $231K | Sell |
10,836
-13,042
| -55% | -$249K | ﹤0.01% | 5257 |
|
|
2016
Q4 | $363K | Buy |
+23,878
| New | +$325K | ﹤0.01% | 5100 |
|
Other funds holding RARX
Morgan Stanley's RARX Position: Q2 2020 in Review
Morgan Stanley sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 319,579 shares — an estimated $15.3M sold.
Morgan Stanley first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $15.3M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Morgan Stanley reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Morgan Stanley sold 319,579 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $15.3M.
- Morgan Stanley first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Morgan Stanley's Ra Pharmaceuticals, Inc. Common Stock position peaked at $15.3M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Morgan Stanley's 13F filing for Q2 2020, filed 14 Aug 2020.